Quest Diagnostics (DGX) Backs At Home Cervical Cancer Screening

• Quest Diagnostics (NYSE:DGX) and Waters Corporation announced a collaboration to expand access to the Onclarity Self-Collection Kit for cervical cancer screening.

• The partnership focuses on at-home sample collection that can be processed through Quest Diagnostics laboratories using the Onclarity HPV assay.

• The two companies aim to widen access to clinically appropriate cervical cancer testing for patients who face barriers to in clinic screening.

• The Onclarity Self-Collection Kit collaboration only captures part of how Quest Diagnostics is repositioning its consumer health testing model. We have also spotted 1 warning sign worth knowing about at Quest Diagnostics.

This push into at home cervical cancer screening is one example of a wider group of healthcare players leaning into remote diagnostics. 34 healthcare AI stocks

Quest Diagnostics is a US based healthcare provider focused on diagnostic testing and services, and its collaboration with Waters Corporation ties that core lab expertise directly into at home cervical cancer screening. For a business with a market value of roughly $26.9b, moves like this show how large scale lab infrastructure can be applied to more consumer centric testing models.

4 things going right for Quest Diagnostics that this headline doesn't cover.

What Quest Diagnostics' at-home HPV move changes in the Narrative

This collaboration leans directly into the Quest Diagnostics Narrative that consumer health testing and advanced diagnostics are key volume drivers. Plugging the Onclarity Self Collection Kit into Quest's lab and distribution footprint aligns with the catalyst that its roughly US$300 million consumer business is an important growth engine and that automation can support complex testing at scale. The partnership also ties into the firm's use of AI enabled systems, since the BD COR platform is part of its broader push for productivity gains. What this update does not resolve is the policy overhang from potential reimbursement pressure, which still features prominently in the risk section of the Quest Diagnostics story.

See how these catalysts shape Quest Diagnostics' path to a $254 fair value .

From here, pay close attention to how Quest Diagnostics reports consumer initiated testing trends and kit volumes once the Onclarity Self Collection program enters broader rollout in 2027, since that is when investors can start to see whether this collaboration materially contributes to its consumer health growth goals.

Add Quest Diagnostics to your Watchlist and get alerts as these catalysts play out.